DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
283	後天性赤芽球癆	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04423367 (ClinicalTrials.gov)	September 13, 2020	5/6/2020	Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment	Safety and Efficacy of Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment: A Prospective Phase II Trial	Acquired Pure Red Cell Aplasia	Drug: bortezomib/dexamethasone	Institute of Hematology & Blood Diseases Hospital	NULL	Recruiting	18 Years	70 Years	All	17	Phase 2	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04423367
(ClinicalTrials.gov)

September 13, 2020

5/6/2020

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment

Safety and Efficacy of Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment: A Prospective Phase II Trial

Acquired Pure Red Cell Aplasia

Drug: bortezomib/dexamethasone

Institute of Hematology & Blood Diseases Hospital

NULL

Recruiting

18 Years

70 Years

All

Phase 2

China